☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
tislelizumab
BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China
August 23, 2021
BeiGene's Tislelizumab in Combination with Asieris' APL-1202 Receive the US FDA's IND Approval for MIBC
June 15, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.
